Note: EPS may not be comparable

Sarepta Therapeutics (NASDAQ: SRPT) reported Q4 EPS of ($0.28), $0.04 better than the analyst estimate of ($0.32). Revenue for the quarter came in at $57.3 million versus the consensus estimate of $56.48 million.

For earnings history and earnings-related data on Sarepta Therapeutics (SRPT) click here.